The progress of neoadjuvant therapy in prostate cancer / 中华泌尿外科杂志

ABSTRACT

Prostate cancer is the second most common tumor in men worldwide, and high-risk and locally advanced prostate cancer are life threatening for patients. With the successful application of neoadjuvant therapy in more and more solid tumors, it’s application in prostate tumors has also been gradually started. Among these studies, neoadjuvant hormonal therapy and neoadjuvant hormonal therapy combined with chemotherapy are currently the most widely used. Although neoadjuvant hormonal therapy has been shown effective in reducing the positive rate of resection margins, it cannot improve the long-term survival of patients. Neoadjuvant hormonal therapy combined with chemotherapy may prolong the non-biochemical recurrence time of high-risk locally advanced patients, but whether patients can ultimately achieve survival benefits still needs to be further clarified in prospective randomized controlled studies.